Table 1.
Patient characteristics
| Patient characteristics | Total cohort |
|---|---|
| Number of patients | 110 |
| Patients from Essen/Münster | 25/85 |
| Age | 72 [11.1] |
| Gleason score | 8 (range: 5–10) |
| Metastases locations | |
| Bone | 102 (92.7%) |
| Lymph nodes | 84 (76%) |
| Liver | 26 (24%) |
| Lung/pleura | 24 (22%) |
| History of previous therapies | |
| Abiraterone | 92 [83.6%] |
| Enzalutamide | 90 [81.8%] |
| Docetaxel | 92 [80.9%] |
| Cabazitaxel | 29 [26.4%] |
| Pre- Lu-PSMA therapy blood parameter | |
| Prostate-specific antigen [ng/ml] | 231.0 [587.5] |
| Lactate dehydrogenase [U/l] | 317.0 [245.0] |
| Aspartate aminotransferase [U/l] | 33.0 [24.0] |
| Alanine transaminase [U/l] | 19.0 [34.0] |
| White blood cell count [/μl] | 6.0 [2.7] |
| Hemoglobin [g/dl] | 10.5 [2.6] |
| Platelets [/μl] | 234.0 [117.0] |
| Lu-PSMA therapy | |
| Number of Lu-PSMA cycles | 3 (range: 1–12) |
| Time between PSMA PET and Lu-PSMA start [days] | 32 [22] |
| Average activity per cycle [GBq] | 6.7 [1.2] |
| Cumulated activity [GBq] | 21.2 [18.9] |
Values are presented as median (inter quartile range) or frequency (percentage of all patients); PSMA prostate-specific membrane antigen, Lu-PSMA 177Lu-PSMA-617 therapy